| Changes in the expression of somatostatin receptor imaging following Y-90 lanreotide therapy for carcinoid tumor: a flare response? | |
| | |
MedLine Citation:
|
PMID: 15764878 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
A 53-year-old man with In-111 octreotide-positive metastatic hepatic carcinoid was referred for Y-90 lanreotide therapy. A diagnostic In-111 lanreotide scan, performed to assess suitability for therapy, showed less uptake in lesions compared with In-111 octreotide. After 3 therapy doses of Y-90 lanreotide, a repeat In-111 lanreotide scan showed intense uptake in old lesions, appearance of new lesions, and uptake in the spleen. This was associated with improvement in flushing and regression of liver size. Computed tomography scan showed stable disease. Increased expression of somatostatin receptors has been observed with In-111 octreotide but not with In-111 lanreotide. If this is a flare response, then pretreatment with "cold" lanreotide may be beneficial before Y-90 lanreotide therapy. |
| | |
Authors:
|
Silvija Popadic; Adil Al-Nahhas; Qais Naili; Jonathan Todd; Karim Meeran |
Related Documents
:
|
2311318 - Accumulation of tc-99m mdp in amyloidosis involving the tongue. 7648738 - Radionuclide imaging in extraskeletal myxoid chondrosarcoma. 21415178 - Continuing medical education: online only: diagnosis of inguinal region hernias with ax... 9379308 - In vivo labeling of schistosoma japonicum cercariae with 35s. 8428248 - Imaging of dialysis access: a review of 67 failing fistulas investigated by intravenous... 22703848 - Sensitivity and specificity of ultrasonography and low-field magnetic resonance imaging... |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: Clinical nuclear medicine Volume: 30 ISSN: 0363-9762 ISO Abbreviation: Clin Nucl Med Publication Date: 2005 Apr |
Date Detail:
|
Created Date: 2005-03-14 Completed Date: 2005-06-28 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7611109 Medline TA: Clin Nucl Med Country: United States |
Other Details:
|
Languages: eng Pagination: 238-40 Citation Subset: IM |
Affiliation:
|
Department of Nuclear Medicine, Hammersmith Hospital and Imperial College, London, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Carcinoid Tumor
/
metabolism,
radionuclide imaging*,
radiotherapy*,
secondary Heterocyclic Compounds / therapeutic use* Humans Liver Neoplasms / metabolism, radionuclide imaging*, radiotherapy*, secondary Male Middle Aged Octreotide / analogs & derivatives*, diagnostic use*, pharmacokinetics Peptides, Cyclic / therapeutic use* Radiopharmaceuticals / diagnostic use, pharmacokinetics, therapeutic use Receptors, Somatostatin / metabolism* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Heterocyclic Compounds; 0/Peptides, Cyclic; 0/Radiopharmaceuticals; 0/Receptors, Somatostatin; 0/indium-111-octreotide; 0/yttrium 90-DOTA-lanreotide; 83150-76-9/Octreotide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: B cell lymphoma: a case with localized involvement of the prostate on F-18-FDG examination.
Next Document: Paravertebral infection (phlegmon) demonstrated by FDG dual-head coincidence imaging in a patient wi...